title: Compatibility of gemcitabine hydrochloride with 107 selected drugs during simulated Y-site injection.
abstract: OBJECTIVE
  To evaluate the physical compatibility of gemcitabine hydrochloride (Gemzar-Eli Lilly and Company) with 107 selected drugs.
  
  
  METHODS
  Controlled experimental trial.
  
  
  METHODS
  Laboratory.
  
  
  METHODS
  Samples of 5 mL gemcitabine (as the hydrochloride salt) 10 mg/mL in 0.9% sodium chloride injection were mixed with 5 mL samples of the selected drugs diluted in 0.9% sodium chloride injection or, if necessary to avoid incompatibilities with the diluent, 5% dextrose injection.
  
  
  METHODS
  Visual examinations of the samples were performed in normal fluorescent light with the unaided eye and using a Tyndall beam (high-intensity monodirectional light) to enhance visualization of small particles and low-level haze. The turbidity of each sample was measured as well. In selected samples, electronic particle content assessment was performed. All of the samples were assessed initially and at 1 and 4 hours.
  
  
  RESULTS
  Most of the drugs were physically compatible with gemcitabine hydrochloride during the 4-hour observation period. However, 15 drug combinations had incompatibilities that included color change, increase in haze or turbidity, particulate formation, and gross precipitation: acyclovir sodium, amphotericin B, cefoperazone sodium, cefotaxime sodium, furosemide, ganciclovir sodium, imipenem-cilastatin sodium, irinotecan, methotrexate sodium, methylprednisolone sodium succinate, mezlocillin disodium, mitomycin, piperacillin sodium, piperacillin sodium/tazobactam sodium, and prochlorperazine edisylate.
  
  
  CONCLUSIONS
  Gemcitabine hydrochloride 10 mg/mL admixed in a compatible infusion solution is physically compatible for 4 hours at room temperature with 92 of 107 tested drugs. Simultaneous Y-site administration of gemcitabine hydrochloride with the 15 drugs resulting in incompatibilities should be avoided.
authors.affiliation: Pharmaceutical Analysis Laboratory, University of Texas, M.D. Anderson Cancer Center, Houston 77030, USA. ltrissel@mdanderson.org
authors.forename: L A
authors.initials: LA
authors.lastname: Trissel
authors.forename: J F
authors.initials: JF
authors.lastname: Martinez
authors.forename: D L
authors.initials: DL
authors.lastname: Gilbert
mesh_terms: D000964:Antimetabolites, Antineoplastic / Q000737:chemistry*; D003841:Deoxycytidine / Q000031:analogs & derivatives* / Q000737:chemistry; D004344:Drug Incompatibility; D008027:Light; D009391:Nephelometry and Turbidimetry; D012965:Sodium Chloride / Q000737:chemistry*; D013997:Time Factors; D000093542:Gemcitabine
chemical_list: D000964:Antimetabolites, Antineoplastic; D003841:Deoxycytidine; D012965:Sodium Chloride; D000093542:Gemcitabine